BiotechTube

Insulin + insulin

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Diabete Type 2

Conditions

Diabete Type 2, Hyperglycemia

Trial Timeline

Jan 1, 2016 → Dec 31, 2019

NCT ID
NCT05752929

About Insulin + insulin

Insulin + insulin is a approved stage product being developed by Rafael Holdings for Diabete Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT05752929. Target conditions include Diabete Type 2, Hyperglycemia.

What happened to similar drugs?

20 of 20 similar drugs in Diabete Type 2 were approved

Approved (20) Terminated (0) Active (0)
✅add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
✅Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
✅Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
✅exenatide and sitagliptin + exenatide and placeboEli LillyApproved
✅Tirzepatide + PlaceboEli LillyApproved
✅LisproEli LillyApproved
✅ToujeoMIRA PharmaceuticalsApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05752929ApprovedCompleted

Competing Products

20 competing products in Diabete Type 2

See all competitors
ProductCompanyStageHype Score
NEX-22A, a prolonged release formulation of liraglutideNanexa ABPhase 1
23
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
29
MKP10241 + PlaceboMankind PharmaPhase 2
42
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
21
LY3209590 + Insulin DegludecEli LillyPhase 1
29
AC2993Eli LillyPhase 3
40
LY3209590 + PlaceboEli LillyPhase 1
29
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
40
LY2963016 + LantusEli LillyPhase 1
29
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
26
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
43
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
40
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
26
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
36
Placebo + LinagliptinEli LillyPhase 3
40
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
43
teplizumab or placeboEli LillyPhase 1
21
LY2428757 + PlaceboEli LillyPhase 2
35
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
40